** Brokerage Piper Sandler says it expects lower EBITDA in Q4 2024 and 2025 for chemical companies due to structural issues in the EU and Asia; says U.S. operations may "carry most of the weight"
** Says it will be hard for the companies to generate significant earnings momentum over the next 12-18 months
** Piper Sandler downgrades Dow Chemical DOW.N and LyondellBasell LYB.N to 'neutral' from 'overweight', and cuts PTs to $53 from $60, and $95 from $112, respectively
** Expects Ecolab ECL.N (maintain "overweight", PT cut to $270 from $305) and Olin OLN.N (maintain "overweight", PT cut to $41 from $51), among others, to be in best position to expand earnings partially on lesser degree of overcapacity in their markets
** Brokerage says it does not expect a rebound in China's chemical demand growth and U.S. pricing and margins will not be enough to drive company earnings
** Says stimulus in China and the EU will have more gradual impact than anticipated and might not address overcapacity
(Reporting by Seher Dareen in Bengaluru)
((Seher.Dareen@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。